These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

176 related items for PubMed ID: 23013440

  • 1. Everolimus is associated with a reduced incidence of cytomegalovirus infection following de novo cardiac transplantation.
    Kobashigawa J, Ross H, Bara C, Delgado JF, Dengler T, Lehmkuhl HB, Wang SS, Dong G, Witte S, Junge G, Potena L.
    Transpl Infect Dis; 2013 Apr; 15(2):150-62. PubMed ID: 23013440
    [Abstract] [Full Text] [Related]

  • 2. Lower incidence of cytomegalovirus infection with everolimus versus mycophenolate mofetil in de novo cardiac transplant recipients: a randomized, multicenter study.
    Viganò M, Dengler T, Mattei MF, Poncelet A, Vanhaecke J, Vermes E, Kleinloog R, Li Y, Gezahegen Y, Delgado JF, RAD A2411 Study Investigators.
    Transpl Infect Dis; 2010 Feb; 12(1):23-30. PubMed ID: 19744284
    [Abstract] [Full Text] [Related]

  • 3. A lower incidence of cytomegalovirus infection in de novo heart transplant recipients randomized to everolimus.
    Hill JA, Hummel M, Starling RC, Kobashigawa JA, Perrone SV, Arizón JM, Simonsen S, Abeywickrama KH, Bara C.
    Transplantation; 2007 Dec 15; 84(11):1436-42. PubMed ID: 18091519
    [Abstract] [Full Text] [Related]

  • 4. From clinical trials to clinical practice: an overview of Certican (everolimus) in heart transplantation.
    Valantine H, Zuckermann A.
    J Heart Lung Transplant; 2005 Apr 15; 24(4 Suppl):S185-90; discussion S210-1. PubMed ID: 15774320
    [Abstract] [Full Text] [Related]

  • 5. Role of immunosuppressive regimen on the incidence and characteristics of cytomegalovirus infection in heart transplantation: a single-center experience with preemptive therapy.
    De Santo LS, Romano G, Mastroianni C, Roberta C, Della Corte A, Amarelli C, Maiello C, Giannolo B, Marra C, Ragone E, Grimaldi M, Utili R, Scardone M, Cotrufo M.
    Transplant Proc; 2005 Apr 15; 37(6):2684-7. PubMed ID: 16182784
    [Abstract] [Full Text] [Related]

  • 6. Impact of de novo everolimus-based immunosuppression on incisional complications in heart transplantation.
    Zuckermann A, Arizon JM, Dong G, Eisen HJ, Kobashigawa J, Lehmkuhl H, Ross H, Pelligrini C, Wang SS, Barten MJ.
    Transplantation; 2011 Sep 15; 92(5):594-600. PubMed ID: 21862955
    [Abstract] [Full Text] [Related]

  • 7. Cytomegalovirus risk factors in renal transplantation with modern immunosuppression.
    Bataille S, Moal V, Gaudart J, Indreies M, Purgus R, Dussol B, Zandotti C, Berland Y, Vacher-Coponat H.
    Transpl Infect Dis; 2010 Dec 15; 12(6):480-8. PubMed ID: 20629971
    [Abstract] [Full Text] [Related]

  • 8. Review of cytomegalovirus infection findings with mammalian target of rapamycin inhibitor-based immunosuppressive therapy in de novo renal transplant recipients.
    Nashan B, Gaston R, Emery V, Säemann MD, Mueller NJ, Couzi L, Dantal J, Shihab F, Mulgaonkar S, Seun Kim Y, Brennan DC.
    Transplantation; 2012 Jun 15; 93(11):1075-85. PubMed ID: 22683823
    [Abstract] [Full Text] [Related]

  • 9. Long-term results of kidney transplantation with cyclosporine- and everolimus-based immunosuppression.
    Iaria G, Pisani F, Iorio B, Lucchesi C, De Luca L, Ielpo B, D'Andria D, Tariciotti L, Tisone G.
    Transplant Proc; 2006 May 15; 38(4):1018-9. PubMed ID: 16757249
    [Abstract] [Full Text] [Related]

  • 10. Influence of everolimus on cyclosporine Neoral pharmacokinetics in Chinese de novo cardiac transplant recipients.
    Wang CH, Chou NK, Wu FL, Ko WJ, Tsao CI, Chi NH, Hsu RB, Wang SS.
    Transplant Proc; 2006 Sep 15; 38(7):2032-4. PubMed ID: 16979990
    [Abstract] [Full Text] [Related]

  • 11. Long-term cardiovascular risk in transplantation--insights from the use of everolimus in heart transplantation.
    Eisen H.
    Nephrol Dial Transplant; 2006 Jul 15; 21 Suppl 3():iii9-13. PubMed ID: 16815858
    [Abstract] [Full Text] [Related]

  • 12. Cyclosporine reduction in the presence of everolimus: 3-month data from a Canadian pilot study of maintenance cardiac allograft recipients.
    Ross H, Pflugfelder P, Haddad H, Cantarovich M, White M, Ignaszewski A, Howlett J, Vaillancourt M, Dorent R, Burton JR, CADENCE Study Group.
    J Heart Lung Transplant; 2008 Feb 15; 27(2):197-202. PubMed ID: 18267227
    [Abstract] [Full Text] [Related]

  • 13. Cardiac allograft vasculopathy by intravascular ultrasound in heart transplant patients: substudy from the Everolimus versus mycophenolate mofetil randomized, multicenter trial.
    Kobashigawa JA, Pauly DF, Starling RC, Eisen H, Ross H, Wang SS, Cantin B, Hill JA, Lopez P, Dong G, Nicholls SJ, A2310 IVUS Substudy Investigators.
    JACC Heart Fail; 2013 Oct 15; 1(5):389-99. PubMed ID: 24621971
    [Abstract] [Full Text] [Related]

  • 14. Prevention of acute rejection and allograft vasculopathy by everolimus in cardiac transplants recipients: a 24-month analysis.
    Viganò M, Tuzcu M, Benza R, Boissonnat P, Haverich A, Hill J, Laufer G, Love R, Parameshwar J, Pulpón LA, Renlund D, Abeywickrama K, Cretin N, Starling RC, Eisen HJ, RAD B253 Study Group.
    J Heart Lung Transplant; 2007 Jun 15; 26(6):584-92. PubMed ID: 17543781
    [Abstract] [Full Text] [Related]

  • 15. Everolimus-based immunosuppressive regimens in lung transplant recipients: impact on CMV infection.
    Rittà M, Costa C, Solidoro P, Sidoti F, Libertucci D, Boffini M, Rinaldi M, Baldi S, Cavallo R.
    Antiviral Res; 2015 Jan 15; 113():19-26. PubMed ID: 25446337
    [Abstract] [Full Text] [Related]

  • 16. Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients.
    Eisen HJ, Tuzcu EM, Dorent R, Kobashigawa J, Mancini D, Valantine-von Kaeppler HA, Starling RC, Sørensen K, Hummel M, Lind JM, Abeywickrama KH, Bernhardt P, RAD B253 Study Group.
    N Engl J Med; 2003 Aug 28; 349(9):847-58. PubMed ID: 12944570
    [Abstract] [Full Text] [Related]

  • 17. Decreased incidence of cytomegalovirus infection with sirolimus in a post hoc randomized, multicenter study in lung transplantation.
    Ghassemieh B, Ahya VN, Baz MA, Valentine VG, Arcasoy SM, Love RB, Seethamraju H, Alex CG, Bag R, DeOliveira NC, Vigneswaran WT, Charbeneau J, Garrity ER, Bhorade SM.
    J Heart Lung Transplant; 2013 Jul 28; 32(7):701-6. PubMed ID: 23664526
    [Abstract] [Full Text] [Related]

  • 18. Clinical experience with Certican (everolimus) in maintenance heart transplant patients at the Medical University of Vienna.
    Zuckermann A.
    J Heart Lung Transplant; 2005 Apr 28; 24(4 Suppl):S206-9; discussion S210-1. PubMed ID: 15774324
    [Abstract] [Full Text] [Related]

  • 19. Cytomegalovirus incidence between everolimus versus mycophenolate in de novo renal transplants: pooled analysis of three clinical trials.
    Brennan DC, Legendre C, Patel D, Mange K, Wiland A, McCague K, Shihab FS.
    Am J Transplant; 2011 Nov 28; 11(11):2453-62. PubMed ID: 21812923
    [Abstract] [Full Text] [Related]

  • 20. Clinical outcome in heart transplant recipients receiving everolimus in combination with dosage reduction of the calcineurin inhibitor cyclosporine A or tacrolimus.
    Fuchs U, Zittermann A, Ensminger SM, Schulz U, Gummert JF.
    Transpl Immunol; 2014 Aug 28; 31(2):87-91. PubMed ID: 24932812
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.